Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 May 1;175(5):1345–1352. doi: 10.1084/jem.175.5.1345

Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation

PMCID: PMC2119205  PMID: 1569402

Abstract

Draining lymph node cells (LNC) from mice immunized with hen egg white lysozyme (HEL) display at their surface antigen-MHC complexes able to stimulate, in the absence of any further antigen addition, HEL peptide- specific, class II-restricted T cell hybridomas. Chloroquine addition to these LNC cultures fails to inhibit antigen presentation, indicating that antigenic complexes of class II molecules and HEL peptides are formed in vivo. MHC class II restriction of antigen presentation by LNC from HEL-primed mice was verified by the use of anti-class II monoclonal antibodies. Coinjection of HEL and the I-Ak-binding peptide HEL 112-129 in mice of H-2k haplotype inhibits the ability of LNC to stimulate I-Ak-restricted, HEL 46-61-specific T cell hybridomas. Similar results are obtained in mice coinjected with the HEL peptides 46-61 and 112-129. Inhibition of T hybridoma activation can also be observed using as antigen-presenting cells irradiated, T cell-depleted LNC from mice coinjected with HEL 46-61 and HEL 112-129, ruling out the possible role of either specific or nonspecific suppressor T cells. Inhibition of T cell proliferation is associated with MHC-specific inhibition of antigen presentation and with occupancy by the competitor of class II binding sites, as measured by activation of peptide- specific T cell hybridomas. These results demonstrate that administration of MHC class II binding peptide competitors selectively inhibits antigen presentation to class II-restricted T cells, indicating competitive blockade of class II molecules in vivo.

Full Text

The Full Text of this article is available as a PDF (827.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adorini L., Appella E., Doria G., Nagy Z. A. Mechanisms influencing the immunodominance of T cell determinants. J Exp Med. 1988 Dec 1;168(6):2091–2104. doi: 10.1084/jem.168.6.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adorini L., Moreno J., Momburg F., Hämmerling G. J., Guéry J. C., Valli A., Fuchs S. Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells. J Exp Med. 1991 Oct 1;174(4):945–948. doi: 10.1084/jem.174.4.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Adorini L., Muller S., Cardinaux F., Lehmann P. V., Falcioni F., Nagy Z. A. In vivo competition between self peptides and foreign antigens in T-cell activation. Nature. 1988 Aug 18;334(6183):623–625. doi: 10.1038/334623a0. [DOI] [PubMed] [Google Scholar]
  4. Adorini L., Nagy Z. A. Peptide competition for antigen presentation. Immunol Today. 1990 Jan;11(1):21–24. doi: 10.1016/0167-5699(90)90006-u. [DOI] [PubMed] [Google Scholar]
  5. Adorini L., Sette A., Buus S., Grey H. M., Darsley M., Lehmann P. V., Doria G., Nagy Z. A., Appella E. Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5181–5185. doi: 10.1073/pnas.85.14.5181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Allen P. M., Unanue E. R. Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. J Immunol. 1984 Mar;132(3):1077–1079. [PubMed] [Google Scholar]
  7. Babbitt B. P., Matsueda G., Haber E., Unanue E. R., Allen P. M. Antigenic competition at the level of peptide-Ia binding. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4509–4513. doi: 10.1073/pnas.83.12.4509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Buus S., Sette A., Colon S. M., Miles C., Grey H. M. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science. 1987 Mar 13;235(4794):1353–1358. doi: 10.1126/science.2435001. [DOI] [PubMed] [Google Scholar]
  9. Demotz S., Grey H. M., Sette A. The minimal number of class II MHC-antigen complexes needed for T cell activation. Science. 1990 Aug 31;249(4972):1028–1030. doi: 10.1126/science.2118680. [DOI] [PubMed] [Google Scholar]
  10. Evavold B. D., Allen P. M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991 May 31;252(5010):1308–1310. doi: 10.1126/science.1833816. [DOI] [PubMed] [Google Scholar]
  11. Gammon G., Geysen H. M., Apple R. J., Pickett E., Palmer M., Ametani A., Sercarz E. E. T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med. 1991 Mar 1;173(3):609–617. doi: 10.1084/jem.173.3.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Guillet J. G., Lai M. Z., Briner T. J., Smith J. A., Gefter M. L. Interaction of peptide antigens and class II major histocompatibility complex antigens. Nature. 1986 Nov 20;324(6094):260–262. doi: 10.1038/324260a0. [DOI] [PubMed] [Google Scholar]
  13. Janeway C. A. Autoimmune disease: immunotherapy by peptides? Nature. 1989 Oct 12;341(6242):482–483. doi: 10.1038/341482a0. [DOI] [PubMed] [Google Scholar]
  14. Lamont A. G., Sette A., Fujinami R., Colón S. M., Miles C., Grey H. M. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules. J Immunol. 1990 Sep 15;145(6):1687–1693. [PubMed] [Google Scholar]
  15. Leighton J., Sette A., Sidney J., Appella E., Ehrhardt C., Fuchs S., Adorini L. Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. J Immunol. 1991 Jul 1;147(1):198–204. [PubMed] [Google Scholar]
  16. Muller S., Adorini L., Juretic A., Nagy Z. A. Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form. J Immunol. 1990 Dec 15;145(12):4006–4011. [PubMed] [Google Scholar]
  17. Oi V. T., Jones P. P., Goding J. W., Herzenberg L. A., Herzenberg L. A. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol. 1978;81:115–120. doi: 10.1007/978-3-642-67448-8_18. [DOI] [PubMed] [Google Scholar]
  18. Ozato K., Mayer N., Sachs D. H. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol. 1980 Feb;124(2):533–540. [PubMed] [Google Scholar]
  19. Ria F., Chan B. M., Scherer M. T., Smith J. A., Gefter M. L. Immunological activity of covalently linked T-cell epitopes. Nature. 1990 Jan 25;343(6256):381–383. doi: 10.1038/343381a0. [DOI] [PubMed] [Google Scholar]
  20. Rock K. L., Benacerraf B. Selective modification of a private I-A allo-stimulating determinant(s) upon association of antigen with an antigen-presenting cell. J Exp Med. 1984 Apr 1;159(4):1238–1252. doi: 10.1084/jem.159.4.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sakai K., Zamvil S. S., Mitchell D. J., Hodgkinson S., Rothbard J. B., Steinman L. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9470–9474. doi: 10.1073/pnas.86.23.9470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sercarz E., Krzych U. The distinctive specificity of antigen-specific suppressor T cells. Immunol Today. 1991 Apr;12(4):111–118. doi: 10.1016/0167-5699(91)90094-A. [DOI] [PubMed] [Google Scholar]
  23. Smilek D. E., Lock C. B., McDevitt H. O. Antigen recognition and peptide-mediated immunotherapy in autoimmune disease. Immunol Rev. 1990 Dec;118:37–71. doi: 10.1111/j.1600-065x.1990.tb00813.x. [DOI] [PubMed] [Google Scholar]
  24. Smilek D. E., Wraith D. C., Hodgkinson S., Dwivedy S., Steinman L., McDevitt H. O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9633–9637. doi: 10.1073/pnas.88.21.9633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith S. C., Allen P. M. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991 Oct 1;147(7):2141–2147. [PubMed] [Google Scholar]
  26. Werdelin O. Chemically related antigens compete for presentation by accessory cells to T cells. J Immunol. 1982 Nov;129(5):1883–1891. [PubMed] [Google Scholar]
  27. Wraith D. C., Smilek D. E., Mitchell D. J., Steinman L., McDevitt H. O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 1989 Oct 20;59(2):247–255. doi: 10.1016/0092-8674(89)90287-0. [DOI] [PubMed] [Google Scholar]
  28. Zamvil S. S., Mitchell D. J., Moore A. C., Kitamura K., Steinman L., Rothbard J. B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature. 1986 Nov 20;324(6094):258–260. doi: 10.1038/324258a0. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES